- Home
- PLMR vs TNGX Comparison
PLMR vs TNGX Comparison
Compare PLMR & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLMR | TNGX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLMR | TNGX |
|---|---|---|
| Price | $129.08 | $19.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $159.14 | $20.00 |
| AVG Volume (30 Days) | 174.2K | ★ 2.7M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.04 | 26.89 |
| EPS | ★ 7.17 | N/A |
| Revenue | ★ $875,967,000.00 | $62,384,000.00 |
| Revenue This Year | $196.24 | N/A |
| Revenue Next Year | $21.31 | N/A |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | ★ 58.16 | 48.29 |
| 52 Week Low | $107.75 | $1.04 |
| 52 Week High | $175.85 | $22.20 |
Technical Indicators
Market Signals| Indicator | PLMR | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.17 | 59.87 |
| Support Level | $117.75 | $6.54 |
| Resistance Level | $135.63 | $21.82 |
| Average True Range (ATR) | 3.54 | 1.26 |
| MACD | 1.09 | -0.19 |
| Stochastic Oscillator | 100.00 | 36.63 |
Price Performance
Historical ComparisonAbout PLMR Palomar Holdings Inc.
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. It provides insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The company's Earthquake product generate high premium.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.